Renalytix surges on takeover approach
4th Mar 2024 11:28
(Sharecast News) - Renalytix surged on Monday after saying it had received an unsolicited takeover approach from "a large and well-capitalised publicly listed strategic diagnostics company".
Read moreRenalytix shares jump on draft US Medicare coverage decision
9th Feb 2024 10:38
(Sharecast News) - Renalytix shares were rocketing on Friday morning, after it announced that the Centers for Medicare and Medicaid Services (CMS) in the US had published a draft local coverage determination (LCD) for its 'KidneyIntelX' and 'kidneyintelX.dkd' testing products, outlining the coverage and pricing for the tests.
Read moreRenalytix kidney test claims allowed by US Patent Office
6th Oct 2023 11:35
(Sharecast News) - Diagnostic artificial intelligence (AI) specialist Renalytix announced an enhancement to its intellectual property portfolio for its KidneyIntelX.dkd test on Friday.
Read moreRenalytix gets KidneyIntelX included in major clinical guidelines
21st Aug 2023 12:39
(Sharecast News) - Renalytix announced on Monday that its signature solution 'KidneyIntelX' has secured a spot in the draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 clinical practice guideline for the evaluation and management of chronic kidney disease.
Read moreRenalytix launches kidney disease test in Arabian Gulf countries
21st Jul 2023 16:11
(Sharecast News) - Renalytix announced the commercial availability of 'kidneyintelX.dkd' testing in six Gulf Cooperation Council (GCC) markets on Friday - Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and the United Arab Emirates.
Read moreRenalytix test gets US FDA marketing authorisation
30th Jun 2023 15:49
(Sharecast News) - Renalytix announced on Friday that the US Food and Drug Administration (FDA) had granted De Novo marketing authorisation for its 'KidneyIntelX.dkd' prognostic test.
Read moreRenalytix secures expanded coverage in Washington, DC area
22nd May 2023 12:18
(Sharecast News) - Kidney disease diagnostics developer Renalytix announced the expansion of insurance coverage in the US for its flagship product KidneyIntelX on Monday.
Read moreRenalytix reports positive study on clinical value of KidneyIntelX
19th Apr 2023 13:52
(Sharecast News) - Biotechnology company Renalytix announced the publication of new case studies in the Diabetic Nephropathy journal on Wednesday, highlighting the clinical value of 'KidneyIntelX' in risk stratification for the management of type-2 diabetes and chronic kidney disease (CKD).
Read moreRenalytix rises on publication of positive evidence
29th Nov 2022 17:14
(Sharecast News) - Renalytix announced new real-world evidence, printed in the Primary Care and Community Health publication, on Tuesday.
Read moreRenalytix reports positive outcomes from Mount Sinai
10th Jun 2022 11:48
(Sharecast News) - Renalytix updated the market on the deployment of its 'KidneyIntelX' bioprognostic testing in 1,112 adult diabetic kidney disease (DKD) patients at Mount Sinai Health System on Friday.
Read moreRenalytix completes financing to support its growth
8th Apr 2022 15:29
(Sharecast News) - Renalytix announced the completion of a $30m (£23.06m) financing package on Friday, to support its growth and for general working capital.
Read moreRevenue rises, losses widen in first half at Renalytix
31st Mar 2022 12:44
(Sharecast News) - Artificial intelligence (AI)-focussed diagnostics company Renalytix reported first-half revenue of $1.3m (£0.99m) in its first half on Thursday, up from $0.4m year-on-year.
Read moreRenalytix hits patient milestone for kidney and diabetes 'biorepository'
29th Mar 2022 09:54
(Sharecast News) - Renalytix announced on Tuesday that it has reached an enrollment milestone for its kidney disease and diabetes medicine platform.
Read moreRenalytix launches new US provider access portal
9th Mar 2022 13:41
(Sharecast News) - Renalytix announced the launch of the new 'myIntelX' provider access portal on Wednesday, to provide access for United States physicians to order 'KidneyIntelX' bioprognostic testing to identify type-2 diabetes patients at the greatest risk of rapid kidney disease progression.
Read moreRenalytix presents new clinical data on KidneyIntelX
24th Feb 2022 13:36
(Sharecast News) - Renalytix announced the presentation of new clinical data for 'KidneyIntelX' bioprognostic testing at the World Congress of Nephrology's annual meeting on Thursday.
Read more